Praktické lékárenství – 1/2019

www.praktickelekarenstvi.cz / Prakt. lékáren. 2019; 15(1e): e3–e14 / PRAKTICKÉ LÉKÁRENSTVÍ e14 MEDICAMENTA NOVA BREXPIPRAZOL 28. Ivkovic J, Lindsten A, George V, et a. Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia. J Clin Psychopharmacol 2019; 39: 13–19. 29. Forbes A, Hobart M, Ouyang J, et al. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. Int J Neuropsychopharmacol 2018; 21: 433–441. 30. Newcomer JW, Eriksson H, Zhang P, et al. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of pha- se 3 clinical studies. Curr Med Res Opin 2018; 34: 2197–2205. 31. Otsuka America Pharmaceutical I. Data on file (REX-024). Safety Profile for REXULTI® (brexpiprazole) as Adjunctive Treatment in MDD, 2018. [cited 2019 Jan 14]. Available from: https://www.rexultihcp.com/mdd/safety 32. Markovic M, Gallipani A, Patel KH, et al. Brexpiprazole. Ann Pharmacother 2017; 51: 315–322. 33. Diefenderfer LA,Iuppa C: Brexpiprazole. A review of a new treatment option for schi- zophrenia and major depressive disorder. Ment Health Clin 2017; 7: 207–212. 34. Moore TJ, Glenmullen J,Mattison DR. Reports of pathological gambling, hypersexuali- ty, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA In- tern Med 2014; 174: 1930–1933. 35. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9–62. 36. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disor- der: a systematic review of the efficacy and safety profile for this newly approved antipsy- chotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015; 69: 978–997. 37. Frankel JS,Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychophar- macol 2017; 7: 29–41.